PaulJTuiteMD

PubMed

• 2 citations
  Ethical, legal, and policy challenges in field-based neuroimaging research using emerging portable MRI technologies: guidance for investigators and for oversight.
  Francis X Shen, Susan M Wolf, Frances Lawrenz, Donnella S Comeau, Kafui Dzirasa
  Journal of Law and the Biosciences. 2024-06-07
• 5 citations
  White matter microstructure in Parkinson's disease with and without elevated rapid eye movement sleep muscle tone.
  Rémi Patriat, Pramod K Pisharady, Sommer Amundsen-Huffmaster, Maria Linn-Evans, Michael Howell
  Brain Communications. 2022-01-01
• 34 citations
  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care
  Brent Bluett, Alexander Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova
  Frontiers in Neurology. 2021-07-01

Journal Articles

• Impulsive behavior and associated clinical variables in Parkinson’s disease.  
  Abosch A, Gupte A, Eberly LE, Tuite PJ, Nance M, Grant JE, Psychosomatics
• A recommended scale for cognitive screening in clinical trials of Parkinson’s disease.  
  Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Troster AI, Uc EY, Mov Disord 25:2501-7
• Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease.  
  Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators (Tuite P; UM Site Investigator), Hyson C, Oakes D, Flagg..., Mov Disord 25:1801-8, 1992-8
• Parkinson Study Group-PROGENI Investigators (Tuite P; UM Site Investigator) Maternal inheritance and mitochondrial DNA variants in familial Parkinson’s disease.  
  Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T, BMC Med Genet 11:53
• The effect of dopamine replacement therapy on haptic sensitivity in Parkinson’s disease.  
  Li KY, Pickett K, Nestrasil I, Tuite P, Konczak J, J Neurol 257:1992-8
• A long-term study of istradefylline in subjects with fluctuating Parkinson’ disease.  
  Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM, Parkinsonism Relat Disord 16:423-6
• T1rho and T2rho MRI in the evaluation of Parkinson’s disease.  
  Nestrasil I, Michaeli S, Liimatainen T, Rydeen CE, Kotz CM, Nixon JP, Garwood M, Hanson T, Tuite PJ, J Neurol 257:964-8
• Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.  
  Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM, Parkinsonism Relat Disord 16:16-20
• A comparison of treatment thresholds in two large Parkinson’s disease clinical trial cohorts.  
  Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, Mov Dis 24(16):2370-2378
• PROGENI Investigators, Coordinators and Molecular Genetic Laboratories; GenePD Investigators, Coordinators and Molecular Genetic Laboratories (Tuite P; UM Site Investi...  
  Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T, BMC Med Genet 22;10:98
• A longitudinal program for biomarker development in Parkinson disease: a feasibility study.  
  Ravina B, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern W, Fahn S, Goetz C, Grate S, Kurlan R, Lang A, Marek K, Kieburtz, Oakes D, Elliott R, Shoulson I, and the Pa..., Mov Disord 24:2081-90
• Mutations in GBA are associated with familial Parkinson diseas susceptibility and age at onset.  
  Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Parkinson Study Group-PROGENI Investigators Inv..., Neurology 72(4):310-6
• Genomewide association study for susceptibility genes contributing to familial Parkinson disease.  
  Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, Coordinators and Molecular Genetic Laborato..., Hum Genet 124(6):593-605
• Variation in GIGYF2 is not associated with Parkinson disease.  
  Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Neurology 72:1886-92
• Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease.  
  Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Mov Disord 2009 24:564-73
• Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.  
  Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC, Parkinson Study Group-PROGENI Investigators (Tuite P; UM Site ..., Neurology 73:279-86
• Haptic perception of object curvature in Parkinson’s disease.  
  Konczak J, Li KY, Tuite PJ, Poizner H, PLoS ONE 2008;3(7):e2625
• Clinical correlates of depressive symptoms in familial Parkinson’s disease  
  Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T, Parkinson’s Study Group-PROGENI Investigators (Tuite P; UM Site Investigator), disease Mov Disord 23(15):2216-2223
• Fatigue in levodopa-naïve subjects with Parkinson’s disease.  
  Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S, Parkinson Study Group ELLDOPA Investigators (Tuite P; UM Site Investigator), Neurology 71:481-5
• Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.  
  22. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A and the Parkinson Study Group PRECEPT Investigators (Tuite P; UM Site Inves..., Arch Neurol 65:716-723
• Reversible cortical blindness (Anton’s syndrome) associated with bilateral occipital EEG abnormalities.  
  Roos KL, Tuite P, Below ME, Pascuzzi RM, Clin Electroencephalogr 21:104-109
• Cerebral vein thrombosis due to hereditary antithrombin III deficiency.  
  Tuite P, Ahmad F, Grant I, Stewart JD, Carpenter S, Ethier R, Can J Neurol Sci 20: 158-161
• Dopa-responsive Parkinsonism phenotype of Machado-Joseph disease - confirmation of 14q CAG expansion.  
  Tuite P, Rogaeva EA, St George-Hyslop PH, Lang AE, Neurol 38: 684-687
• Idiopathic generalized myokymia (Isaacs’s syndrome) with hand posturing resembling dystonia.  
  Tuite P, Navarette C, Bril V, Lang AE, Mov Disord 11: 448-449
• Atypical dopa-responsive Parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.  
  Tuite P, Provias JP, Lang AE, Journal Neurol Neurosurg Psychiatry 61: 523-527
• Join now to see all

Books/Book Chapters

•  
  Tuite P, Thomas C, Ruekert L, Fernandez HEditors: Springer Publishing.
•  
  Tuite PEditors: Galvez-Jimenez N and Tuite P.Cambridge Press
•  
  Chapter: Ironing out the details 
  Bower M and Tuite PEditors: Hubert Fernandez and Marcelo Merello. Demos Medical.
•  
  Chapter: Neurodegeneration with brain iron accumulation 
  Bower M and Tuite PEditors: N Galvez-Jimenez and P Tuite.
•  
  Tuite P
•  
  Chapter: New treatment modalities in Parkinson’s Disease 
  Tuite P, Riss J and Brauer LHEditors: Nestor Galvez-Jimenez.Parthenon Publishing, Abingdon, UK
•  
  Chapter: Chapter 14: Tolcapone 
  Tuite P and Weisenberg BEditors: Rajesh Pahwa, MD, Kelly Lyons, PhD, and William C. Koller, MD.Marcel Dekker , New York
•  
  Chapter: Syndromes of Disordered Posture and Movement 
  Tuite P and Lang A EEditors: Bruce Berg.McGraw Hill
• Join now to see all

Abstracts/Posters

• Abstract on MR spectroscopy.
  Grüetter R, Tuite P, Twelfth Scientific Meeting of ISMRM, Kyoto, Japan
• Ugurbil. Assessment of brain iron and a neuronal marker in patients with Parkinson’s disease using novel MRI contrasts.
  Tuite, P, Michaeli S, Sorce D, Oz G, Garwood M, Mov Disord 21(S15): S454
• Assessment of Brain Iron and a Neuronal Marker in Patients with Parkinson’s disease Using Novel MRI Contrasts.
  Michaeli S, Sorce D, Oz G, Ugurbil K, Garwood M, Tuite, P, Mov Disord 21(9):1545
• Baseline comparison of the PRECEPT and DATATOP clinical trial cohorts.
  Parkinson Study Group. (Tuite P, U of M Site Investigator, Mov Disord 21(Suppl 13):S121
• Identification of Risk Loci for Progressive Supranuclear Palsy.
  Hutton M, Coon K, Melquist S, Pearson J, Baker M, Craig DW, Dickson DW, Huentelman MJ, Tuite P, Bower M, Adamson JL, Crook R, Stephan D, Society for Neuroscience
• A randomized controlled trial of etilevodopa in Parkinson’s disease patients with motor fluctuations.
  Parkinson Study Group (Schwid S, presenter) (Tuite P, U of M Site Investigator), Mov Disord 20(9):1237
• CEP-1347 treatment fails to favorably modify the progression of Parkinson’s disease (PRECEPT) study.
  Shoulson I and Parkinson Study Group (PSG) PRECEPT Investigators (Tuite P, U of M Site Investigator), Neurology 67(1):185
• Safety of rasagiline in combination with serotonin reuptake inhibitors.
  Parkinson Study Group (Schwid S, presenter) (Tuite P, U of M Site Investigator), Ann Neurol 58(S9):S56
• Rasagiline is effective and well tolerated in the treatment of Parkinson’s disease (PD) patients with levodopa-related motor fluctuations receiving concomitant dopamin...
  Parkinson Study Group (Elmer L, presenter) (Tuite P, U of M Site Investigator), Ann Neurol 58(S9):S54
• Influence of Rehabilitation on Gaze Control in Progressive Supranuclear Palsy.
  DiFabio RP, Zampieri C, Tuite P, Konczak J, Society of Neuroscience
• Weight Perception is Impaired in Parkinson’s disease.
  Konczak J, Krawczewski K, Pickett KA, Tuite P, Maschke M, Society for Neuroscience
• Safety of rasagiline in elderly Parkinson’s disease (PD) patients.
  Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson Study Group TEMPO and PRESTO Invesigators. (Tuite P, U of M Site Investigator), Mov Disord 20(Suppl 10):S81
• Rasagiline does not promote tyramine pressor responses.
  Parkinson Study Group. (Tuite P, U of M Site Investigator, Mov Disord 20(Suppl 10):S133
• Proton MR Spectroscopy of Substantia Nigra in the Human Brain at 4 Tesla.
  Oz G, Tuite P, Terpstra M, Tkac I, Aia P, Lowary J, Grüetter R, the 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's disease and ..., Toronto, Ontario, Canada
• Voxel-based morphometry and diffusion tensor imaging.
  Lehericy S, Luciana M, Kendi ATK, Ugurbil K, Tuite P, Parkinson’s disease. 21stAnnual Symposium on Etiology, Pathogenesis and ..., Washington, DC
• Evidence for a gene on chromosome 10 that influences both PD and AD susceptibility.
  Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group. (Tuite P, U of M Site Investigator), Neurology 2004;62(Suppl 5):A27
• The North American survey of placement and adjustment techniques for deep brain stimulation.
  Ondo W, Tuite P, and others, American Academy of Neurology 56th Annual Meeting, San Francisco, California
• Evaluation of the long-duration benefit from levodopa: Results from the ELLDOPA (Earlier vs. Later LevoDOPA) Study.
  Fahn S, Parkinson Study Group. (Tuite P, U of M Site Investigator), Mov Disord 18(9):1085-1086
• Progressive Ataxia and Palatal Tremor (PAPT): Clinical and radiological features.
  Tuite P, Gray T, Torun N, Sharpe J, Lang AE, the Tenth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's disease and ..., Miami, Florida
• Vertical Gaze Enhanced with Biofeedback for Patients with Progressive Supranuclear Palsy: Evidence for Movement Related Plasticity in a Chronic Progressive Neurologica...
  Di Fabio RP, Zampieri C, Tuite P, Konczak J, The 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's disease and..., Toronto, Ontario, Canada
• Everything you ever wanted to know about imaging blepharospasm patients.
  Tuite P, The 26th Annual International Conf & Scientific Symposium:Beni Essential Blepharospasm RF...
• High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.
  Tuite P, PD Monitor & Commentary
• Lee Silverman voice treatment helps Parkinson’s disease patients retain vital communication skills M.D.
  Tuite P, News December
• Parkinson’s disease. An overview of treatments and research.
  Tuite P, Minnesota Medicine
• Depression in a Cohort of 1335 Individuals with Familial Parkinson Disease.
  Pankratz N, Halter C, Rudolph A, Shults C, Nichols W, Foroud T, Parkinson Study Group – PROGENI Investigators (Tuite P, U of M Site Investigator), Neurology 68(1):A37
• Join now to see all

Lectures

• Movement Disorders for healthcare professionals. 
  The Geritom Education Center
• Pathophysiology of Parkinson's disease: How it Relates to Swallowing Function and Medical Treatment. 
  Seventh Annual Dysphagia Research Society Meeting, New Orleans, Louisiana
• Drug Treatment for the Management of Parkinson’s Disease: Dopamine Agonist. 
  The First Annual Update in Movement Disorders and General Neurology at the Cleveland Clinic, Florida
• Present and Future Therapies for Parkinson’s Disease. 
  The GRECC National Conference, “Problems of the Aging Brain: Diagnosis & Management
• Other Medications in Parkinson’s Disease. 
  The Fourth Annual Parkinson’s Disease Symposium at the Ohio State University Medical Center
• Practical perspectives on evaluation and management of Parkinsonism and mobility. 
  Center on Aging Quarterly Conference
• Developments in Movement Disorders for Residents . 
  Mayo Clinic
• Device Based Treatments in Neurology. 
  University of Minnesota, President’s Commissioned Interdisciplinary Conference on Medical Devices
• Health & the Life Sciences. 
  Evan Presentation to State Legislators on Parkinson’s disease during visit to UM
• Breakfast roundtable with TEVA. 
  Radisson Hotel, Minneapolis, Minnesota
• Clinical Neuroscience: Through the Lens of Technology. 
  Mini-Medical School
• Organization of Neuroimaging Symposium at the Center for MRI Research (CMRR) to discuss use of imaging for multiple sclerosis. 
  Parkinson’s disease, Huntington’s disease and other neurological conditions
• Activa educational roundtable discussion on Innovative. 
  Theory and Technology for Activa Therapy
• Neurologic Devices. 
  Biomedical Engineering Institute,Chair
• Geriatric Pharmacotherapy. 
  Parkinson’s disease
• Moderator for Research Strategies Session. 
  Scientists in Aging Research Retreat, Minneapolis, MN
• Parkinson’s disease update for neurologists in Willmar. 
  Minnesota
• An Update on Parkinson’s Research. 
  The public Educational Conference on Parkinson’s disease
• Parkinson’s disease update, seminar sponsored. 
  American Parkinson’s Disease Association, Twin Cities
• Inservice lecture on movement disorders at end of life. 
  St. Joseph’s Hospital
• Exploring Environmental Links to Disease: A Look at Parkinson’s disease and Non-Hodgkin’s Lymphoma Conference. 
  Sioux Falls, South Dakota
• Sharing information on Parkinson’s disease from three author’s perspectives. 
  Minnesota
• Staying on the Job with Parkinson’s disease. 
  H.J. Cummins Star Tribune Article on Work and Parkinson’s disease
• Fitting New Drugs Into Disease States: Parkinson's Disease. 
  Continuing Education in Pharmacy, University of Minnesota
• Headache. 
  Presented at the CME course on "Practical Solutions for Your Chronic Patients" Symposium, Minneapoli
• Join now to see all

Other

• Parkinson’s disease program multiple talks and panel discussion. 
  Paul Joseph Tuite
  http://mnpdforum.roundtablelive.org/
• 30 minute TPT. 
  Paul Joseph Tuite, Channel 2 public TV
  TV program on Parkinson’s disease